Curriculum Vitae


Jacqueline R. Wyatt
jwyatt@JL-SciEdit.com


Objectives
To provide scientific editorial services, ranging from polishing to extensive re-writing particularly in the fields of biochemistry, molecular biology and chemistry. To provide consulting services in the areas of bioinformatics and oligonucleotide chemistry and biochemistry.

Education:
Ph.D. Biophysical Chemistry. University of California, Berkeley. January, 1990.
B.S. Chemistry (English minor); B.S. Secondary Education. University of Wyoming. May, 1984. Graduated highest honors, Phi Beta Kappa.

Professional and Research Experience:
August 2000-present. Consultant for several oligonucleotide-based biotechnology companies. Free-lance scientific editor and writer. 

February 2002-September 2002. Cooley-Godward, LLP, San Diego, CA. Researcher, Biotechnology patent infringement case.

January 1992-August 2000. ISIS Pharmaceuticals. Carlsbad, CA. 
    1998 Associate Director, Structural Biology.
    1996 Associate Director, Ibis Program.
    1994 Assistant Director.
    1992 Senior Scientist.

January 1990-January 1992. Jane Coffin Childs Postdoctoral Fellow, Yale University, New Haven, CT.
    Professor Joan A. Steitz, mentor.

September 1985-January 1990. Graduate Student, University of California, Berkeley.
    Professor Ignacio Tinoco, Jr., advisor.         

September 1984-August 1985. Scientist, Analytical Research, Dorsey Laboratories, Sandoz, Inc. Lincoln, NE.

May 1981-August 1984. Undergraduate Research (1981, NSF Fellow; 1984, Kuehn Fellow), University of Wyoming.

    Professor David A. Jaeger, advisor. 


Publications:

Ecker DJ, Sampath R, Willett P, Wyatt JR, Samant V, Massire C, Hall TA, Hari K, McNeil JA, Büchen-Osmond C, Budowle B. (2005) BMC Microbiology 5, 19. “The Microbial Rosetta Stone Database III:Global and Emerging Infectious Microorganisms.”

Zhang H, Taylor J, Luther D, Johnston J, Murray S, Wyatt JR, Watt AT, Koo S, York-DeFalco C, Stecker K, Dean NM. (2003) J Pharmacol Exp Ther. 307, 24-33. “Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis.”

Patel NA, Eichler DC, Chappell DS, Illingworth PA, Chalfant CE, Yamamoto M, Dean NM, Wyatt JR, Mebert K, Watson JE, Cooper DR. (2003) J Biol Chem. 278, 1149-1157. “The protein kinase C beta II exon confers mRNA instability in the presence of high glucose concentrations.”

Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM. (2001) Nucleic Acids Res. 29, 1293-1299. “Fully modified 2' MOE oligonucleotides redirect polyadenylation.”

Patel NA, Chalfant CE, Watson JE, Wyatt JR, Dean NM, Eichler DC, Cooper DR. (2001) J. Biol. Chem. 276 22648-22654. “Insulin regulates alternative splicing of protein kinase C beta II through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells.”

Matveeva OV, Tsodikov AD, Giddings M, Freier SM, Wyatt JR, Spiridonov AN, Shabalina SA, Gesteland RF, Atkins JF. (2000) Nucleic Acids Res. 28, 2862-2865. “Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity.”

Beaudoing E, Freier S, Wyatt JR, Claverie, J-M, Gautheret D. (2000) Genome Res. 10, 1001-10. “Patterns of variant polyadenylation signal usage in human genes.”

Vickers TA, Wyatt JR, Freier SM. (2000) Nucleic Acids Res. 15, 1340-1347. “Effects of RNA secondary structure on cellular antisense activity.”

Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH. (1999) RNA 5, 1458-1469. “Predicting oligonucleotide affinity to nucleic acid targets.”

Taylor JK, Zhang Q-Q, Wyatt JR, Dean NM. (1999) Nature Biotech. 17, 1097-1100. “Induction of endogenous bcl-xS through the control of bcl-x pre-mRNA splicing by antisense oligonucleotides.”

Kung P-P, Casper MD, Cook KL, Wilson-Lingardo L, Risen LM, Vickers TA, Ranken R, Blyn LB, Wyatt JR, Cook PD, Ecker DJ. (1999) J. Med. Chem. 42, 4705-4713. “Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents.”

Wyatt JR, Stein CA. (1999) In Applications of Antisense Therapies to Restenosis (L.E. Rabbini, ed.), Kluwer Academic Publishers, Boston. “Oligonucleotides containing the G-quartet sequence motif.”

Stoddart CA, Rabin L, Hincenbergs M, Moreno ME, Linquist-Stepps V, Leeds JM, Truong LA, Wyatt JR, Ecker DJ, McCune JM. (1998) Antimicrob. Agents Chemother. 42, 2113-2115. “Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320.”

An H, Cummins LL, Griffey RH, Bharadwaj R, Haly BD, Fraser AS, Wilson-Lingardo L, Risen LM, Wyatt JR, Cook PD. (1997) J. Am. Chem. Soc. 119, 3696-3708. “Solution Phase Combinatorial Chemistry. Discovery of Novel Polyazapyridinophanes with Potent Antibacterial Activity by a Solution Phase Simultaneous Addition of Functionalities Approach.”

Konings DAM, Wyatt JR, Ecker DJ, Freier SM. (1997) J. Med. Chem. 40, 4386-4395. “Strategies for rapid deconvolution of combinatorial libraries: comparative evaluation using a model system.”

Wyatt JR, Davis PW, Freier, SM. (1996) Biochemistry 35, 8002-8008. “Kinetics of G-quartet-mediated tetramer formation.”

Freier SM, Konings DAM, Wyatt JR, Ecker DJ. (1996) Bioorganic Med. Chem. 4, 717-725. “Mutational SURF: a strategy for improving lead compounds identified from combinatorial libraries.”

Konings DAM, Wyatt JR, Ecker DJ, Freier, SM. (1996) J. Med. Chem. 39, 2710-2719. “Deconvolution of combinatorial libraries for drug discovery: theoretical comparison of pooling strategies.”

Wilson-Lingardo L, Davis PW, Ecker DJ, Hebert N, Acevedo O, Sprankle K, Brennan T, Schwarcz L, Freier SM, Wyatt JR. (1996) J. Med. Chem. 39, 2720-2726. “Deconvolution of combinatorial libraries for drug discovery: experimental comparison of pooling strategies.”

Davis PW, Vickers TA, Wilson-Lingardo L, Wyatt JR, Guinosso CJ, Sanghvi YS, DeBaets EA, Acevedo OL, Cook PD, Ecker DJ. (1995) J. Med. Chem. 38, 4363-4366. “Drug leads from combinatorial libraries.”

Ecker DJ, Wyatt JR, Vickers T, Buckheit R, Roberson J, Imbach, J-L. (1995) Nucleosides and Nucleotides 14, 1117-1127. “Novel guanosine quartet structure binds to the HIV envelope and inhibits envelope-mediated cell fusion.” 

Freier SM, Konings DAM, Wyatt JR, Ecker DJ. (1995) J. Med. Chem. 38, 344-352. “Deconvolution of combinatorial libraries for drug discovery: a model system.”

Puglisi JD, Wyatt JR. (1995) Meth. Enzym. 261, 323-349. “Biochemical and NMR studies of RNA conformation.”

Wyatt JR et al. (1994) Proc. Natl. Acad. Sci. USA 91, 1356-1360. “Combinatorially selected quanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.”

Buckheit RW, Roberson JL, Lackman-Smith C, Wyatt JR, Vickers TA, Ecker DJ. (1994) AIDS Res. Hum. Retrov. 10, 1497-1506. “Potent and specific inhibition of HIV-envelope-mediated fusion and virus binding by a G-quartet-forming oligonucleotide.”

Bennett CF, Chiang M-Y, Wilson-Lingardo L, Wyatt JR. (1994) Nucleic Acids Res. 22, 3202-3209. “Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides.”

Wyatt JR, Tinoco, I. (1993) In The RNA World (R. Gesteland and J. Atkins, eds.), Cold Spring Harbor Laboratory Press. "RNA structural elements and RNA function." 

Wyatt JR, Sontheimer EJ, Steitz JA. (1992) Genes Dev. 6, 2542-2553. "Site-specific crosslinking of mammalian U5 snRNP to the 5' splice site prior to the first step of premessenger RNA splicing."

Wyatt JR, Chastain M, Puglisi JD. (1991) BioTechniques 11, 764-769. "Synthesis and purification of large amounts of RNA oligonucleotide."

Wyatt JR, Puglisi JD, Tinoco I. (1991) Acc. Chem. Res. 24, 152-158. "RNA pseudoknots." 

Wyatt JR, Puglisi JD, Tinoco I. (1990) J. Mol. Biol. 214, 455-470. "RNA pseudoknots: stability and loop size requirements."

Puglisi JD, Wyatt JR, Tinoco I. (1990) J. Mol. Biol. 214, 437-453. "Conformation of an RNA pseudoknot."

Wyatt JR. (1990) "RNA Pseudoknots: Effect of Loop Sequence and Size on Conformational Equilibria." University of CA, Berkeley, Ph.D. Dissertation.

Puglisi JD, Wyatt JR, Tinoco I. (1990) Biochemistry 29, 4215-4226. "Solution conformation of an RNA hairpin."

Tinoco I, Puglisi JD, Wyatt JR. (1990) In Nucleic Acids and Molecular Biology 4 (F. Eckstein and D. Lilley, eds.), Springer-Verlag, Berlin. "RNA folding."

Wyatt JR, Puglisi JD, Tinoco, I. (1989) BioEssays 11, 100-106. "RNA folding: pseudoknots, loops & bulges."

Wyatt JR, Walker GT. (1989) Nucleic Acids Res. 17, 7833-7842. "Deoxynucleotide-containing oligoribonucleotide duplexes: stability and susceptibility to RNase V1 and RNase H."

Tinoco I, Aboul-ela F, Hardin C, Puglisi J, Varani G, Walker GT, Wolk S, Wyatt J. (1989) In Frontiers of Macromolecular Science (T. Saegusa, T. Higashimura and A. Abe, eds.) pp. 519-524, Blackwell Scientific Publications, Oxford. "Nucleic acids from A to Z." 

Puglisi JD, Wyatt JR, Tinoco I. (1988) Nature 331, 283-286. "A pseudoknotted RNA oligonucleotide."

Wyatt JR, Puglisi JD, Tinoco I. (1988) In Molecular Biology of RNA 94 (T. Cech, ed.), pp. 25-32, Alan R. Liss, Inc, New York, NY. "Pseudoknotted RNA oligonucleotides." 

Tinoco I, Davis PW, Hardin CC, Puglisi JD, Walker GT, Wyatt JR. (1988) Cold Spring Harbor Symp. Quant. Biol. 52, 135-146. "RNA structure from A to Z." 

Jaeger DA, Wyatt JR, Robertson RR. (1985) J. Org. Chem. 50, 1467-1470. "Monochlorination of n-alkylphenyl ethers in micellar sodium dodecyl sulfate."

Wyatt JR. (1984) "Regioselectivity in monohalogenation reactions of alkyl phenyl ethers." University of Wyoming, Senior Thesis.


Grants:
Phase I SBIR, 1998. “Targeting Rho: A bacterial termination factor.”

Phase I SBIR, 1995. “Synthesis and Selection of PLA2 Inhibitors.”

Jane Coffin-Childs Postdoctoral Fellowship, 1990-1992.

Patents:
Ecker DJ, Acevedo O, Hebert N, Davis PW, Wyatt JR, Kiely JS. (Isis Pharmaceuticals, Inc, USA). US Patent 5,925,732. “Chemical reaction apparatus for performing multiple reaction on a surface and collecting the product.”

Cook PD, Ecker DJ, Wyatt J, Bruice TW, Anderson K, Hanecak R, Vickers T, Davis P, Freier SM, Sanghvi YS, Brown-Driver V. (Isis Pharmaceuticals, Inc, USA). US Patent 5,698,391. “Synthetic Unrandomization of Random oligomer Fragments (SURF), a nonenzymic method for determining oligomers with specific target activity.”

Ecker DJ, Wyatt JR, Imbach J-L. (ISIS Pharmaceuticals, Inc, USA) US Patent 5,523,389. “Inhibition of human immunodeficiency virus by tetramer-forming d(GGGG)-containing oligonucleotides.”

Draper KG, Crooke ST, Mirabelli CK, Ecker DJ, Hanecak RC, Anderson KP, Brown-Driver VL, Wyatt JR. (Isis Pharmaceuticals, Inc, USA). US Patent 5,514,577. “Oligonucleotide therapies for modulating the effects of herpes viruses.”

Hanecak RC, Anderson KP, Bennett CF, Chiang M-Y, Brown-Driver VL, Ecker DJ, Vickers TA, Wyatt JR, Imbach J-L. (ISIS Pharmaceuticals, Inc, USA). US Patent 5,952,490. “Oligonucleotides with a core sequence of four guanine residues and their use in the inhibition of phospholipases and of viral gene expression.”

Ecker DJ, Wyatt J, Bruice TW, Anderson K, Hanecak RC, Vickers T, Davis P. (ISIS Pharmaceuticals, Inc, USA US Patent 5,672,472. “Synthetic unrandomization of oligomer fragments.”


Letters of Reference Available on Request